CSPIA
CBAY

Cary Street Partners Investment Advisory’s Cymabay Therapeutics CBAY Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,900
Closed -$328K – 727
2023
Q4 		$328K Sell
13,900
-6,100
-31% -$109K 0.02% 516
2023
Q3 		$298K Sell
20,000
-10,000
-33% -$133K 0.02% 478
2023
Q2 		$329K Hold
30,000
– – 0.02% 421
2023
Q1 		$262K Sell
30,000
-10,000
-25% -$80.1K 0.02% 424
2022
Q4 		$251K Hold
40,000
– – 0.02% 430
2022
Q3 		$140K Hold
40,000
– – 0.01% 474
2022
Q2 		$118K Buy
40,000
+10,000
+33% +$23.9K 0.01% 489
2022
Q1 		$93K Buy
+30,000
New +$94.4K 0.03% 271

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cary Street Partners Investment Advisory's CBAY Position: Q1 2024 in Review

Cary Street Partners Investment Advisory sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 13,900 shares — an estimated $328K sold.

Cary Street Partners Investment Advisory first reported a position in CBAY in Q1 2022 and held it in 8 quarters. The position peaked at $329K in Q2 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Cary Street Partners Investment Advisory reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 13,900 Cymabay Therapeutics shares in Q1 2024, an estimated $328K.
  • Cary Street Partners Investment Advisory first reported a position in Cymabay Therapeutics in Q1 2022 and held it in 8 quarters.
  • Cary Street Partners Investment Advisory's Cymabay Therapeutics position peaked at $329K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Cary Street Partners Investment Advisory's 13F filing for Q1 2024, filed 30 Apr 2024.